BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghidewon M, Wald HS, McKnight AD, De Jonghe BC, Breen DM, Alhadeff AL, Borner T, Grill HJ. Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms. Diabetes Obes Metab 2022;24:1010-20. [PMID: 35129264 DOI: 10.1111/dom.14663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Zhao X, Dong X, Zhang Y, Zou H, Jin Y, Guo W, Zhai P, Chen X, Kharitonenkov A. Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates. Cell Metab 2023:S1550-4131(23)00001-3. [PMID: 36706758 DOI: 10.1016/j.cmet.2023.01.001] [Reference Citation Analysis]
2 Liu K, Liu B, Wittert GA, Thompson CH, Hutchison AT, Heilbronn LK. Intermittent fasting increases growth differentiation factor 15 in females with overweight or obesity but not associated with food intake. Obes Res Clin Pract 2022:S1871-403X(22)00137-5. [PMID: 36509678 DOI: 10.1016/j.orcp.2022.12.001] [Reference Citation Analysis]
3 Valenzuela-Vallejo L, Chrysafi P, Bello-Ramos J, Bsata S, Mantzoros CS. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity. Metabolism 2022;133:155237. [PMID: 35700837 DOI: 10.1016/j.metabol.2022.155237] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]